NEU neuren pharmaceuticals limited

Wider autism efficacy potential for nnz-2566, page-3

  1. 144 Posts.
    mw03, you're right mate. IGF-1 is being tested because it is already approved by the FDA for growth related conditions. It is definitely a competitor.

    There are a couple of reasons why nnz-2566 walks all over IGF-1 though.
    1. nnz-2566 is orally available while IGF-1 requires injections.
    2. IGF-1 cannot be used with older patients in all diseases as it will promote excessive growth, while nnz-2566 does not have that issue.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$14.65
Change
0.470(3.31%)
Mkt cap ! $1.820B
Open High Low Value Volume
$14.36 $14.75 $14.36 $9.182M 629.3K

Buyers (Bids)

No. Vol. Price($)
1 830 $15.50
 

Sellers (Offers)

Price($) Vol. No.
$13.88 3476 6
View Market Depth
Last trade - 15.59pm 10/07/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.